HomeCompareATGGF vs NNN

ATGGF vs NNN: Dividend Comparison 2026

ATGGF yields 5000.00% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATGGF wins by $62217131802825.33M in total portfolio value
10 years
ATGGF
ATGGF
● Live price
5000.00%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$62217131802825.35M
Annual income
$59,861,980,287,378,210,000.00
Full ATGGF calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — ATGGF vs NNN

📍 ATGGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATGGFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATGGF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATGGF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATGGF
Annual income on $10K today (after 15% tax)
$425,000.00/yr
After 10yr DRIP, annual income (after tax)
$50,882,683,244,271,480,000.00/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, ATGGF beats the other by $50,882,683,244,271,480,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATGGF + NNN for your $10,000?

ATGGF: 50%NNN: 50%
100% NNN50/50100% ATGGF
Portfolio after 10yr
$31108565901412.69M
Annual income
$29,930,990,143,689,105,000.00/yr
Blended yield
96.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

ATGGF
No analyst data
Altman Z
34.8
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATGGF buys
0
NNN buys
0
No recent congressional trades found for ATGGF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATGGFNNN
Forward yield5000.00%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$62217131802825.35M$25.5K
Annual income after 10y$59,861,980,287,378,210,000.00$2,622.67
Total dividends collected$62057786341622.61M$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ATGGF vs NNN ($10,000, DRIP)

YearATGGF PortfolioATGGF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$510,700$500,000.00$10,735$614.96+$500.0KATGGF
2$24,410,935$23,864,485.98$11,572$708.43+$24.40MATGGF
3$1,092,192,501$1,066,072,800.30$12,531$819.53+$1092.18MATGGF
4$45,746,366,951$44,577,720,975.17$13,633$952.29+$45746.35MATGGF
5$1,793,932,828,410$1,744,984,215,772.56$14,909$1,111.84+$1793932.81MATGGF
6$65,871,973,805,320$63,952,465,678,921.49$16,392$1,304.77+$65871973.79MATGGF
7$2,265,146,887,602,700$2,194,663,875,631,007.20$18,129$1,539.52+$2265146887.58MATGGF
8$72,954,689,148,998,180$70,530,981,979,263,280.00$20,173$1,827.08+$72954689148.98MATGGF
9$2,201,076,182,660,884,700$2,123,014,665,271,456,500.00$22,597$2,181.81+$2201076182660.86MATGGF
10$62,217,131,802,825,350,000$59,861,980,287,378,210,000.00$25,491$2,622.67+$62217131802825.33MATGGF

ATGGF vs NNN: Complete Analysis 2026

ATGGFStock

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Full ATGGF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this ATGGF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATGGF vs SCHDATGGF vs JEPIATGGF vs OATGGF vs KOATGGF vs MAINATGGF vs ADCATGGF vs EPRTATGGF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.